Renal function and cardiovascular risk in hypertensive patients

Journal of Hypertension

Volumn 23, Issue 10, 2005, Pages 1787-1788

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ALBUMINURIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; PRIORITY JOURNAL;

EID: 29244473850     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000183526.58499.65     Document Type: Editorial

References (15)

1. Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22:1635-1639.
2. Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13 (suppl 3):S165-S168.
3. Hailpern SM, Cohen HW, Alderman MH. Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens 2005; 23:1809-1816.
4. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
5. Chobanian A, Bakris GL, Black HR, Cushman W, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572.
6. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL, Ruilope LM. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616-1622.
7. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; 66:S45-S49.
8. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14:881-887.
9. Segura J, Campo C, Rodicio J, Ruilope LM. ACE inhibition and appearance of renal events in hypertensive nephrosclerosis. Hypertension 2001; 18:645-649.
10. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized Trial. Ann Intern Med 2001; 134:629-636.
11. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57:728-734.
12. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110:1557-1563.
13. Zanchetti A, Hansson L, Dahlöf B, Julius S, Menard J, Warnold I, Wedel H, for the HOT Study Group. Benefit and harm of low-dose aspirin in well treated hypertensives at different baseline cardiovascular risk. J Hypertens 2000; 20:2301-2307.
14. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45:473-484.
15. Curtis BM, Levin A, Parfrey PS. Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. Med Clin North Am 2005; 89:511-523.